Shares of medical device company Integra LifeSciences (NASDAQ:IART)
fell 23% in the morning session after it reported third-quarter sales that missed expectations and provided a weak financial outlook. The company's revenue of $402.1 million fell short of Wall Street's projections. While its adjusted earnings per share of $0.54 surpassed estimates, this was overshadowed by disappointing forward-looking guidance. Integra's revenue forecast for the fourth quarter came in at $430 million, well below what analysts had anticipated. Adding to investor concerns, the company also lowered its adjusted earnings per share guidance for the full year.
Integra LifeSciences (IART) posted mixed Q3 2025 results, beating earnings estimates by 21.7% but missing revenue targets. The stock rose on the profit beat despite soft forward guidance.
Medical device company Integra LifeSciences (NASDAQ:IART) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 5.6% year on year to $402.1 million. Next quarter’s revenue guidance of $430 million underwhelmed, coming in 5.9% below analysts’ estimates. Its non-GAAP profit of $0.54 per share was 24.1% above analysts’ consensus estimates.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Dallas, TX – October 17, 2025 – Sanara MedTech Inc. (NASDAQ: SMTI), a company focused on surgical and chronic wound care, finds itself in the spotlight today as a bottom market performer, with its stock experiencing a notable decline. Despite this recent downturn, a significant portion of Wall Street analysts maintain that
Canton, MA – Organogenesis Holdings Inc. (NASDAQ: ORGO), a prominent player in the regenerative medicine sector, has recently endured a period of significant stock weakness, leaving investors questioning the trajectory of this advanced wound care specialist. The company's shares have faced considerable pressure, marked by notable declines in recent months, fueled
Shares of medical device company Integra LifeSciences (NASDAQ:IART)
fell in the afternoon session after Truist kept a Hold rating on the shares. The analyst mentioned in a research note that they expected “healthy” Q3 revenue and earnings across the medical technology sector but also braced for “stock volatility.” The note also stated that new money felt notably absent from the space and that there could be excessive reactions to anything counter to crowded positioning. This news came as Integra LifeSciences had previously announced it would release its third-quarter financial results on October 30.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, the collective 6.5% gain for healthcare stocks has fallen short of the S&P 500’s 24.7% rise.
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations. As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sell its medications through Medicaid at these reduced prices. The move comes as the administration intensifies pressure on drugmakers to make prices more affordable. While pricing controls can often be a headwind, the market's positive reaction suggests that investors may see this voluntary agreement as a way to resolve regulatory uncertainty, providing a clearer path forward for the industry.
Integra LifeSciences’s stock price has taken a beating over the past six months, shedding 39.3% of its value and falling to $13.34 per share. This might have investors contemplating their next move.
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth.
A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.
Shares of medical device company Integra LifeSciences (NASDAQ:IART)
fell 3.6% in the afternoon session after the U.S. Food and Drug Administration (FDA) issued a warning letter regarding violations at its Boston, MA facility.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the surgical equipment & consumables - specialty stocks, including Integra LifeSciences (NASDAQ:IART) and its peers.
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names.
But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
A number of stocks fell in the morning session after markets continued to decline, as investors grew cautious ahead of a key speech by Federal Reserve Chair Jerome Powell.
Medical device company Integra LifeSciences (NASDAQ:IART) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $415.6 million. The company expects next quarter’s revenue to be around $415 million, close to analysts’ estimates. Its non-GAAP profit of $0.45 per share was 4.4% above analysts’ consensus estimates.
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
